Table 1 Characteristics, laboratory data, and treatments of SLE patients with and without LN
LN patients (N = 12) | SLE patients without LN (N = 12) | |
|---|---|---|
Female: male | 10:2 | 11:1 |
Age in years | 17.34 (11–27) | 17.93 (12–27.8) |
Laboratory data | ||
ANA (+) | 12 (100%) | 12 (100%) |
Anti-dsDNA Ab (+) | 12 (100%) | 12 (100%) |
Anti-dsDNA Ab level (IU/ml)* | 790.04 ± 257.39 | 508.25 ± 277.07 |
DRVVT and/or IgG/IgM anticardiolipin Ab (+) | 4 (33.3%) | 3 (25%) |
WBC count (× 103/ml) | 6292.20 ± 4097.73 | 5632.50 ± 2435.47 |
Hemoglobin (g/dl)** | 9.63 ± 1.92 | 11.9 ± 1.36 |
Platelet count (× 103/ml) | 210.00 ± 99.10 | 220.17 ± 96.94 |
C3 (mg/ml)** | 40.67 ± 18.45 | 76.16 ± 18.79 |
C4 (mg/ml)** | 7.41 ± 3.78 | 13.52 ± 5.35 |
Treatments (ever used) | ||
Corticosteroid | 12 (100%) | 12 (100%) |
MP pulse therapy** | 11 (91.7%) | 3 (25%) |
CTX pulse therapy** | 9 (75%) | 1 ( 8.33%) |
HCQ | 12 (100%) | 12 (100%) |
AZA | 5 (41.7%) | 6 (50%) |
CsA | 7 (58.3%) | 6 (50%) |
MTX | 3 (25%) | 2 (16.7%) |
MMF | 5 (41.7%) | 4 (33.3%) |